Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis
© 2022. The Author(s)..
Fibroblast growth factor-21 (FGF-21) performs a wide range of biological functions in organisms. Here, we report for the first time that FGF-21 suppresses thrombus formation with no notable risk of bleeding. Prophylactic and therapeutic administration of FGF-21 significantly improved the degree of vascular stenosis and reduced the thrombus area, volume and burden. We determined the antithrombotic mechanism of FGF-21, demonstrating that FGF-21 exhibits an anticoagulant effect by inhibiting the expression and activity of factor VII (FVII). FGF-21 exerts an antiplatelet effect by inhibiting platelet activation. FGF-21 enhances fibrinolysis by promoting tissue plasminogen activator (tPA) expression and activation, while inhibiting plasminogen activator inhibitor 1 (PAI-1) expression and activation. We further found that FGF-21 mediated the expression and activation of tPA and PAI-1 by regulating the ERK1/2 and TGF-β/Smad2 pathways, respectively. In addition, we found that FGF-21 inhibits the expression of inflammatory factors in thrombosis by regulating the NF-κB pathway.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Scientific reports - 12(2022), 1 vom: 10. Jan., Seite 400 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Shuai [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.02.2022 Date Revised 26.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-021-00906-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335485243 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335485243 | ||
| 003 | DE-627 | ||
| 005 | 20240229154152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-021-00906-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM335485243 | ||
| 035 | |a (NLM)35013379 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Shuai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2022 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Fibroblast growth factor-21 (FGF-21) performs a wide range of biological functions in organisms. Here, we report for the first time that FGF-21 suppresses thrombus formation with no notable risk of bleeding. Prophylactic and therapeutic administration of FGF-21 significantly improved the degree of vascular stenosis and reduced the thrombus area, volume and burden. We determined the antithrombotic mechanism of FGF-21, demonstrating that FGF-21 exhibits an anticoagulant effect by inhibiting the expression and activity of factor VII (FVII). FGF-21 exerts an antiplatelet effect by inhibiting platelet activation. FGF-21 enhances fibrinolysis by promoting tissue plasminogen activator (tPA) expression and activation, while inhibiting plasminogen activator inhibitor 1 (PAI-1) expression and activation. We further found that FGF-21 mediated the expression and activation of tPA and PAI-1 by regulating the ERK1/2 and TGF-β/Smad2 pathways, respectively. In addition, we found that FGF-21 inhibits the expression of inflammatory factors in thrombosis by regulating the NF-κB pathway | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Plasminogen Activator Inhibitor 1 |2 NLM | |
| 650 | 7 | |a Smad2 Protein |2 NLM | |
| 650 | 7 | |a Smad2 protein, mouse |2 NLM | |
| 650 | 7 | |a Transforming Growth Factor beta |2 NLM | |
| 650 | 7 | |a fibroblast growth factor 21 |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factors |2 NLM | |
| 650 | 7 | |a 62031-54-3 |2 NLM | |
| 650 | 7 | |a Factor VII |2 NLM | |
| 650 | 7 | |a 9001-25-6 |2 NLM | |
| 650 | 7 | |a Extracellular Signal-Regulated MAP Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.24 |2 NLM | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 700 | 1 | |a Jia, Haibo |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhihang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Xiaochen |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Muhua |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jiarui |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Junyan |e verfasserin |4 aut | |
| 700 | 1 | |a He, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Teng |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zongbao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shijie |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Yukai |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Xinghao |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Guiping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Deshan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 12(2022), 1 vom: 10. Jan., Seite 400 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:10 |g month:01 |g pages:400 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-021-00906-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 1 |b 10 |c 01 |h 400 | ||